Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Sep
13
Today In Oncology
Novel ADC Under Study in Previously Treated EGFR-Mutated NSCLC
New Subcutaneous Amivantamab Combo Dosing Schedule Shows Safety and Efficacy in EGFR-Positive NSCLC
STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach
Hypofractionated vs Conventional Radiotherapy in Phase III Trial for LS-SCLC
Tarlatamab and Anti-PD-1 Therapy as First-Line Maintenance for ES-SCLC
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo